Sai Parenterals Restricted, a Hyderabad-based pharmaceutical producer, has raised Rs 50 crore in fairness funding from a consortium of institutional buyers. The funding spherical was led by Samarsh Capital, Vyom Companions, and funds related to Blue Lotus Capital.
The corporate stated the capital can be used to gas its international growth technique, together with acquisitions in regulated markets, enhancement of its manufacturing footprint, and diversification of its product portfolio.
“We’re working diligently to construct a world-class pharmaceutical firm that adheres to the best international requirements,” stated Anil Karusala, Managing Director of Sai Parenterals. “This fairness infusion will permit us to accumulate high-potential worldwide property and mental property, develop our geographical presence, and improve our capabilities.”
Based in 2001, Sai Parenterals operates throughout the pharmaceutical worth chain—from analysis and growth to manufacturing and export. It serves two major enterprise verticals: branded export formulations and contract growth and manufacturing (CDMO) providers. The corporate’s choices span sterile injectables, oral solids and liquids, and topical preparations.
Sai Parenterals at present operates 5 services in India, with choose models authorised by worldwide regulators together with TGA (Australia), WHO-GMP, SAPRA, and GCC authorities. It has a rising presence in South Asia, Africa, the Center East, and different rising markets.
Traders cited the corporate’s execution capabilities and worldwide development potential as key elements behind their participation within the spherical.
“Our funding displays confidence in Sai Parenterals’ fundamentals and its potential to emerge as a world chief,” stated Sandeep Shenoy, Managing Companion at Samarsh Capital.
That is the second funding by Blue Lotus Capital within the firm. “By partnering with a formidable participant in sterile injectables, we intention to speed up inexpensive, high-quality healthcare options for international markets,” stated Harikrishnan S, Managing Companion at Blue Lotus.
The funding comes at a time when Indian pharmaceutical companies are increasing their international attain, significantly in sterile injectables and CDMO providers, amid rising demand for cost-effective manufacturing and complicated formulations.
Sai Parenterals stated it’ll proceed to pursue inorganic development alternatives whereas constructing a science-led, capital-efficient platform serving each regulated and rising markets.
Edited by Megha Reddy
